Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC plus pyrotinib after trastuzumab failure in HER2-positive recurrent or metastatic breast cancer
ChiCTR2300067600Phase 2Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Feb 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and pyrotinib in breast cancer, sponsored by Chongqing University Cancer Hospital. Primary endpoints: Objective response rate and Safety. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
disitamab vedotinpyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2300067600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067600.